These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16729872)

  • 1. Novel concepts of statin therapy for cardiovascular risk reduction in hypertension.
    Varughese GI; Patel JV; Lip GY; Varma C
    Curr Pharm Des; 2006; 12(13):1593-609. PubMed ID: 16729872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?
    Mays ME; Dujovne CA
    Curr Atheroscler Rep; 2008 Feb; 10(1):45-52. PubMed ID: 18366985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of statins on novel risk markers.
    Cignarella A; Bolego C; Paoletti R
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):361-6. PubMed ID: 14696629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of statins: do they matter?
    Gotto AM; Farmer JA
    Curr Opin Lipidol; 2001 Aug; 12(4):391-4. PubMed ID: 11507323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW; Lefer DJ
    Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and cardioprotection--more than just lipid lowering?
    Ludman A; Venugopal V; Yellon DM; Hausenloy DJ
    Pharmacol Ther; 2009 Apr; 122(1):30-43. PubMed ID: 19318042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of statins in endothelial dysfunction in hypertension.
    Sarkar K; Sinha AK; Mehta JL
    Curr Opin Cardiol; 2006 Jul; 21(4):316-21. PubMed ID: 16755200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of statin use on endothelial function: from bench to clinics.
    Martínez-González J; Badimon L
    Curr Pharm Des; 2007; 13(17):1771-86. PubMed ID: 17584107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Thromb Res; 2017 Feb; 150():90-95. PubMed ID: 28068529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins in nephrotic syndrome: a new weapon against tissue injury.
    Buemi M; Nostro L; Crascì E; Barillà A; Cosentini V; Aloisi C; Sofi T; Campo S; Frisina N
    Med Res Rev; 2005 Nov; 25(6):587-609. PubMed ID: 16075407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-lipid-lowering effects of statins on atherosclerosis.
    Rosenson RS
    Curr Cardiol Rep; 1999 Sep; 1(3):225-32. PubMed ID: 10980846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.